

=> fil wpix

FILE 'WPIX' ENTERED AT 09:05:36 ON 07 MAY 2004  
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE LAST UPDATED: 5 MAY 2004 <20040505/UP>  
MOST RECENT DERWENT UPDATE: 200429 <200429/DW>  
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,  
PLEASE VISIT:  
[http://www.stn-international.de/training\\_center/patents/stn\\_guide.pdf](http://www.stn-international.de/training_center/patents/stn_guide.pdf) <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE  
<http://thomsonderwent.com/coverage/latestupdates/> <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER  
GUIDES, PLEASE VISIT:  
<http://thomsonderwent.com/support/userguides/> <<<

>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT  
DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX  
FIRST VIEW - FILE WPIFV. FREE CONNECT HOUR UNTIL 1 MAY 2004.  
FOR FURTHER DETAILS: <http://www.thomsonderwent.com/dwpifv> <<<

>>> NEW! IMPROVE YOUR LITIGATION CHECKING AND INFRINGEMENT  
MONITORING WITH LITALERT. FIRST ACCESS TO RECORDS OF IP  
LAWSUITS FILED IN THE 94 US DISTRICT COURTS SINCE 1973.  
FOR FURTHER DETAILS:  
<http://www.thomsonscientific.com/litalert> <<<

>>> THE DISPLAY LAYOUT HAS BEEN CHANGED TO ACCOMMODATE THE  
NEW FORMAT GERMAN PATENT APPLICATION AND PUBLICATION  
NUMBERS. SEE ALSO:  
<http://www.stn-international.de/archive/stnews/news0104.pdf> <<<

>>> SINCE THE FILE HAD NOT BEEN UPDATED BETWEEN APRIL 12-16  
THERE WAS NO WEEKLY SDI RUN <<<

=> d que 125

L1 ( 24020)SEA FILE=WPIX ABB=ON PLU=ON A61K007-00/IPC  
L2 ( 11826)SEA FILE=WPIX ABB=ON PLU=ON A61K007-06/IPC  
L3 ( 776)SEA FILE=WPIX ABB=ON PLU=ON D08-B07/MC  
L4 ( 89690)SEA FILE=WPIX ABB=ON PLU=ON D21/DC  
L5 ( 485)SEA FILE=WPIX ABB=ON PLU=ON (?TELOMERA? OR TEL OMER? OR  
?TELO MERA?)/TI,BIX,TT  
L6 ( 8)SEA FILE=WPIX ABB=ON PLU=ON L5 AND (L1 OR L2 OR L3 OR L4)  
L7 ( 25262)SEA FILE=WPIX ABB=ON PLU=ON (A61K048-00 OR A61K031-19 OR  
A61K031-4745 OR A61K031-56)/IPC  
L8 ( 103237)SEA FILE=WPIX ABB=ON PLU=ON (B01-D02 OR B02-E OR B02-P OR  
B04-B03A OR B04-B03C OR B04-E01 OR B06-D02 OR B06-D09 OR  
B06-D18 OR B07-A04 OR B08-B OR B10-E04 OR B14-D06B OR B14-R02  
OR D05-H12A OR D05-H12D)/MC  
L9 ( 12031)SEA FILE=WPIX ABB=ON PLU=ON (C01-D02 OR C02-E OR C02-P OR  
C04-B03A OR C04-B03C OR C04-E01 OR C06-D02 OR C06-D09 OR  
C06-D18 OR C07-A04 OR C08-B OR C10-E04 OR C14-D06B OR C14-R02)/  
MC  
L10 ( 118967)SEA FILE=WPIX ABB=ON PLU=ON (L7 OR L8 OR L9) NOT (C14-R02 OR  
B14-R02)/MC  
L11 ( 4750)SEA FILE=WPIX ABB=ON PLU=ON (C14-R02 OR B14-R02)/MC

L12 ( 3108) SEA FILE=WPIX ABB=ON PLU=ON L10 AND ((L1 OR L2 OR L3 OR L4)  
 OR L11)  
 L13 ( 363) SEA FILE=WPIX ABB=ON PLU=ON L12 AND L2  
 L14 ( 345) SEA FILE=WPIX ABB=ON PLU=ON L13 AND (PY<2002 OR PRY<2002 OR  
 AY<2002)  
 L15 ( 74) SEA FILE=WPIX ABB=ON PLU=ON L14 AND (?HAIR? (5A) (?REDUC? OR  
 ?REGU? OR ?MODU? OR ?IMPED? OR ?INHIB? OR ?SLOW? OR ?STOP? OR  
 ?BLOCK? OR ?RUPT? OR ?VENT? OR ?AGON? OR ?HALT?))/BIX  
 L16 ( 8) SEA FILE=WPIX ABB=ON PLU=ON L14 AND (?HAIR? (5A) ?REMOV?)  
 L17 ( 6) SEA FILE=WPIX ABB=ON PLU=ON L14 AND (?DEPIL? OR DE PIL?)  
 L18 ( 81) SEA FILE=WPIX ABB=ON PLU=ON L15 OR L16 OR L17  
 L19 89 SEA FILE=WPIX ABB=ON PLU=ON L18 OR L6  
 L20 8 SEA FILE=WPIX ABB=ON PLU=ON L19 AND ?TELOMER?/BIX  
 L21 3 SEA FILE=WPIX ABB=ON PLU=ON L20 NOT (1999-444196/AN OR  
 2000-400055/AN OR 2000-412129/AN OR 2004-157106/AN OR 2004-2391  
 17/AN)  
 L23 14 SEA FILE=WPIX ABB=ON PLU=ON (1983-45402K/AN OR 1984-277375/AN  
 OR 1985-159178/AN OR 1986-119079/AN OR 1992-096580/AN OR  
 1993-153849/AN OR 1993-167280/AN OR 1995-328081/AN OR 1997-3103  
 50/AN OR 1997-448705/AN OR 2000-545818/AN OR 2001-229036/AN OR  
 2001-582276/AN OR 2002-454495/AN)  
 L24 14 SEA FILE=WPIX ABB=ON PLU=ON L23 AND (L1 OR L2 OR L3 OR L4 OR  
 L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13)  
 L25 17 SEA FILE=WPIX ABB=ON PLU=ON L21 OR L24

=> d l25 all abeq tech abex 1-17

L25 ANSWER 1 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 2003-486262 [46] WPIX  
 DNC C2003-130619  
 TI Cellular aging inhibitor for preventing aging of skin, stomach, intestine,  
 liver and kidney, comprises solvent extract of Ganoderma lucidum.  
 DC B04  
 PA (NONO-N) NONOGAWA SHOJI KK  
 CYC 1  
 PI JP 2003012539 A 20030115 (200346)\* 4 A61K035-84  
 ADT JP 2003012539 A JP 2001-201225 20010702  
 PRAI JP 2001-201225 20010702  
 IC ICM A61K035-84  
 ICS A23L001-28; A23L001-30; **A61K007-00**; A61K007-48; A61P001-00;  
 A61P001-16; A61P013-12; A61P017-00; A61P043-00  
 AB JP2003012539 A UPAB: 20030719  
 NOVELTY - Cellular aging inhibitor or a **telomere** shortening  
 inhibitor comprises a solvent extract of Ganoderma lucidum.  
 ACTIVITY - Dermatological; Hepatotropic; Nephrotropic.  
 MECHANISM OF ACTION - Cellular aging inhibitor; **Telomerase**  
 inhibitor.  
 In a test, human normal skin fibroblast was seeded in a culture  
 medium containing hot water extract of black reishi mushroom, bovine serum  
 (10%) and ascorbic acid magnesium phosphate at 37 deg. C for 7-9 days.  
 After cultivation, the cell was dispersed in phosphoric acid buffer (pH  
 6.8) containing trypsin (0.025%) and ethylene diamine tetra acetate  
 (0.02%). The number of cells after cultivation was increased compared to  
 before cultivation which showed that black reishi mushroom had a good  
**telomerase** inhibitor effect.  
 USE - Used for preventing aging of skin, stomach, intestine, liver  
 and kidney.  
 Dwg.0/0  
 FS CPI

FA AB; DCN  
 MC CPI: B04-A08D; B14-N17  
 TECH UPTX: 20030719  
 TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The solvent used for the extraction of black reishi mushroom is water, lower alcohol and/or liquid polyhydric alcohol.

ABEX UPTX: 20030719  
 EXAMPLE - Dried black reishi mushroom (20 g) was added to purified water (400 ml) and extracted at 95-100degreesC for 2 hours. The filtrate was concentrated and frozen to obtain black reishi mushroom extract.

L25 ANSWER 2 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 2003-221439 [21] WPIX

DNC C2003-056213

TI Reducing mammalian hair growth comprises applying **telomerase** inhibitor to selected skin area.

DC B05 D16 D21

IN AHLUWALIA, G S; STYCZYNSKI, P

PA (AHLU-I) AHLUWALIA G S; (STYC

CYC 101

PI WO 2003002077 A2 20030109

RW: AT BE CH CY DE DK EA

NL OA PT SD SE SL SZ

W: AE AG AL AM AT AU AZ

DM DZ EC EE ES FI GE

KZ LC LK LR LS LT LU

RO RU SD SE SG SI SK

ZW

US 2003012755 A1 20030116 (200321)

EP 1401379 A2 20040331 (200424) EN

R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT

RO SE SI TR

ADT WO 2003002077 A2 WO 2002-US18702 20020612; US 2003012755 A1 US 2001-893252 20010627; EP 1401379 A2 EP 2002-734785 20020612, WO 2002-US18702 20020612

FDT EP 1401379 A2 Based on WO 2003002077

PRAI US 2001-893252 20010627

IC ICM A61K007-00; A61K048-00

ICS A61K007-06; A61K031-19; A61K031-4745; A61K031-56

AB WO2003002077 A UPAB: 20030328

NOVELTY - Reducing hair growth comprises applying a **telomerase** inhibitor to a selected area of skin.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) reducing mammalian hair growth which comprises selecting an area of skin including hair follicles and applying a compound that reduces **telomerase** levels, **telomerase** mRNA expression or promotes the erosion of **telomeric** DNA in the hair follicles to the skin, and

(2) a composition comprising the **telomerase** inhibitor, a carrier and at least one of an emollient, thickener, humectant, powder or skin penetration aid.

ACTIVITY - None given in the source material.

MECHANISM OF ACTION - **Telomerase** inhibitor.

A composition containing AZT (10 weight%) in vehicle containing water (68%), ethanol (16%), propylene glycol (15%), dipropylene glycol (5%), benzyl alcohol (4%) and propylene carbonate (2%) was tested using Golden Syrian Hamster assay. A vehicle containing AZT (10%) was applied to an organ of the animal. Inhibition of flank organ hair growth was demonstrated following the topical administration of the composition. The reduction of hair growth was calculated after applications (one

GILLETTE CO

2007-00 <--

IT KE LS LU MC MW MZ

CN CO CR CU CZ DE DK

IN IS JP KE KG KP KR

MZ NO NZ OM PH PL PT

UG US UZ VN YU ZA ZM

*Applicants*

application per day for 5 days a week). The hair mass value was 2.10 plus or minus 1.8 mg and percentage inhibition was 22 plus or minus 7.

USE - Used for reducing unwanted mammalian (e.g. human) hair growth (preferably androgen stimulated hair growth) and in a cosmetic (claimed).

ADVANTAGE - The composition reduces hair growth by at least 15 (preferably 20)% when tested in the Golden Syrian Hamster assay.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B01-D02; B02-E; B02-P; B04-B03A; B04-B03C; B04-E01; B06-D02; B06-D09; B06-D18; B07-A04; B08-B; B10-E04; B14-D06B; B14-R02; D05-H12A; D05-H12D; **D08-B07**

TECH UPTX: 20030328

TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Components: The **telomerase** inhibitor comprises floxacin, TMPyP4, **telomerase** inhibitor I, **telomerase** inhibitor IV, **telomerase** inhibitor V, AZT, rubromycin, purpurumycin, 3'-deoxy-2:3'-didehydrothymidine, dideoxyinosine, (TTAGGG)<sub>3</sub>, levofloxacin, carbosvir, ACGTTGAGGGGCATC, 2-(3(trifluoromethyl)phenyl)isothiazolin-3-one, ursodeoxycholic acid, diazaphilonic acid, alterperyleneol, 5-azacytidine, 3,4,9,10-perylene-tetracarboxylic diimide-based ligand, 10H-indolo(3,2-b)quinoline, 2'-O-MeRNA **telomerase** oligomer, 2'-O-alkyl RNA **telomerase** oligomer, fomivirsen, a cationic porphyrin, diazaphilonic acid, **telomerase** inhibitor II, **telomerase** inhibitor III, **telomerase** inhibitor VI, **telomerase** inhibitor VII or **telomerase** inhibitor VIII. Preferred Composition: The composition also includes a second component that also causes a reduction in hair growth.

ABEX UPTX: 20030328

ADMINISTRATION - The application amount is 10-3000 mug/cm<sup>2</sup> topically to the skin of the face, a leg, an arm, an armpit or on the torso, or in conjunction with the shaving or a woman with hirsutism (claimed).

L25 ANSWER 3 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 2003-057488 [05] WPIX

DNC C2003-014671

TI Inhibitor against replicative senescence of human keratinocytes, useful for treating oral diseases such as trauma-caused inflammation, traumatic ulcer, angular cheilosis, comprises retinoic acid as active ingredient.

DC B05 **D21**

IN MIN, B M; MIN, B

PA (MINB-I) MIN B M; (MINB-I) MIN B

CYC 2

PI US 2002123526 A1 20020905 (200305)\* 22 A61K031-203

KR 2002011918 A 20020209 (200305) A61K031-203

US 6566399 B2 20030520 (200336) A01N037-00

ADT US 2002123526 A1 US 2001-922070 20010803; KR 2002011918 A KR 2001-46911 20010803; US 6566399 B2 US 2001-922070 20010803

PRAI KR 2001-46911 20010803; KR 2000-44972 20000803

IC ICM A01N037-00; A61K031-203

ICS A61K007-16

AB US2002123526 A UPAB: 20030121

NOVELTY - An inhibitor (I) against replicative senescence of human keratinocytes, comprises a retinoic acid (II) as active ingredient.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a prophylactic or therapeutic agent for oral disease, containing (II), where the oral disease is chosen from trauma-caused inflammation, exelcymosis-caused inflammation, burn-caused inflammation, traumatic ulcer, and angular cheilosis;

(2) a cosmetic purpose containing (II); and

(3) a prophylactic or therapeutic agent for wound-caused dermatitis and skin senescence containing (II).

ACTIVITY - Antiinflammatory; Antiulcer; Vulnerary; Dermatological.  
No biological data available.

MECHANISM OF ACTION - Inhibitor of replicative senescence of human mucosal keratinocytes and human epidermal keratinocytes (claimed); Decreases the expression levels of pRb and p16(INK4A) proteins; Prevents loss of **telomerase** activity resulting from repeated proliferation.

To investigate expression levels of pRb and p16(INK4A) proteins in human oral keratinocytes (NHOK) that were exposed to all trans retinoic acid, Western blot analysis Min B.M. et al., Int. J. Oncol., 1995, 7, 249-256 was performed using anti-mouse Rb (IFB) monoclonal antibody and anti-human p16 (C-20) polyclonal antibody. After probing with each of the respective antibodies, the membrane was stained with 1X Ponceau S stain for 10 minutes to reveal the total protein loading per lane.

Results showed that the pRb protein level of NHOK in vehicle control was similar with other population doubling level (PDL) numbers. However, in all-trans retinoic acid-treated NHOK, the amount of pRb protein was extremely low in the early culture at PDL 18 and gradually increased in the cells at high PDL numbers.

At low PDL, all-trans retinoic acid-treated NHOK had much lower pRb protein levels than the vehicle control corresponding PDL, but had higher levels according to the increase of PDL. Also, the intracellular p16(INK4A) protein level in all-trans retinoic acid-treated oral keratinocytes was significantly lower than that of the vehicle control at any given number. Thus, all-trans retinoic acid induces the in vitro life span extension of oral keratinocytes by decreasing the intracellular p16(INK4A) protein level.

The intracellular p16(INK4A) protein level confirmed from senescent cells of the all-trans retinoic acid-treated NHOK at PDL28 was similar to vehicle-treated control, but all-trans retinoic acid-treated NHOK having lower PDL had notably decreased.

This showed that all-trans retinoic acid maintains **telomerase** activity in NHOK and induces the in vitro life span extension of the human oral keratinocytes by decreasing the intracellular p16(INK4A) protein level.

USE - (I) inhibits replicative senescence of human mucosal keratinocytes (including human oral mucosal keratinocytes) and human epidermal keratinocytes (claimed).

(I) can be used as a prophylactic or therapeutic agent for oral diseases such as trauma-caused inflammation, exelcymosis-caused inflammation, burn-caused inflammation, traumatic ulcer, and angular cheilosis, which are caused by senescence of human oral mucosal keratinocytes.

In addition (I) can inhibit against skin senescence and thus be used for a cosmetic purpose, and can be used as a prophylactic or therapeutic agent for wound-caused dermatitis and skin senescence.

Dwg.0/6

FS

CPI

FA

AB; DCN

MC

CPI: B10-C04A; B14-C03; B14-H01B; B14-H04; B14-N05; B14-N17; B14-R01;  
D08-B

TECH

UPTX: 20030121

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Inhibitor: (I) contains retinoic acid chosen from all-trans retinoic acid, 3,4-didehydroretinoic acid, and 9-cis retinoic acid. Preferably, (I) contains all-trans retinoic acid.

ABEX

UPTX: 20030121

ADMINISTRATION - (I) is administered by oral or parenteral route, and

preferably by parenteral injection in a dosage of 100-2000 (preferably 100-1000) mg/kg body weight for adults.

EXAMPLE - None given.

L25 ANSWER 4 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 2002-454495 [48] WPIX  
 DNC C2002-129190  
 TI Regulating mammalian skin or hair cell proliferation and differentiation by administering nucleic acids encoding peptides derived from N-terminal region of human parathyroid hormone (hPTH) or hPTH-related protein.  
 DC B04 D16 D21  
 IN HOLICK, M F  
 PA (HOLI-I) HOLICK M F  
 CYC 25  
 PI WO 2002028420 A2 20020411 (200248)\* EN 56 A61K038-29  
 RW: AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR  
 W: AU CA JP KR US  
 AU 2001096585 A 20020415 (200254) A61K038-29  
 EP 1349565 A2 20031008 (200370) EN A61K038-29  
 R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR  
 US 2004013719 A1 20040122 (200407) A61K048-00 <--  
 ADT WO 2002028420 A2 WO 2001-US31082 20011005; AU 2001096585 A AU 2001-96585 20011005; EP 1349565 A2 EP 2001-977469 20011005, WO 2001-US31082 20011005; US 2004013719 A1 WO 2001-US31082 20011005, US 2003-398449 20030723  
 FDT AU 2001096585 A Based on WO 2002028420; EP 1349565 A2 Based on WO 2002028420  
 PRAI US 2000-238134P 20001006; US 2003-398449 20030723  
 IC ICM A61K038-29; A61K048-00  
 ICS A61K007-06; A61K007-48; A61K009-127; A61K031-59; A61K031-7088; A61P017-00; A61P035-00; C12N005-08; C12N015-88  
 ICI A61K031:59, A61K038:29; A61K038-29; A61K031:59  
 AB WO 200228420 A UPAB: 20020730  
 NOVELTY - Inhibiting proliferation or enhancing differentiation of mammalian skin or hair cell (mSHC) by administering to mSHC, a nucleic acid molecule (I) encoding a peptide (II) having 3 amino acids, has 10% sequence identity with 34 amino acid N-terminal region of human parathyroid hormone (hPTH) or hPTH-related protein (hPTHrP). Inducing proliferation of mSHC is also performed by administering (I) to mSHC.  
 DETAILED DESCRIPTION - Inhibiting proliferation or enhancing differentiation of (M1)-(M2) mSHC, comprises:  
 (a) administering to mSHC, (I) encoding (II), which when expressed is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured Human keratinocytes, or in vivo in mouse skin by inhibiting skin cell proliferation hair cycle progression or hair cell growth; or  
 (b) SHC of a mammal involves administering to the mammal, (I) and an active vitamin compound, where (II) encoded by (I) when expressed, is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes; or  
 in vivo in mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth.  
 Inducing (M3) proliferation of mSHC involves administering to mSHC, (I) which encodes (II), which when expressed is capable of blocking the inhibition of proliferation or stimulation of differentiation in vitro of cultured human keratinocytes by PTH(1-34), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) or PTHrP (1-34), or in vivo in mouse skin by stimulating skin cell proliferation or accelerating hair cycle progression or stimulating hair cell growth.  
 INDEPENDENT CLAIMS are also included for the following:

(1) a composition (C1) comprising a proliferation inhibiting or differentiation enhancing amount of (I) encoding (II), contained within a liposome (where (II), when expressed is capable of inhibiting proliferation or enhancing differentiation in vitro of cultured human keratinocytes or in vivo mouse skin by inhibiting skin cell proliferation or hair cycle progression or hair cell growth (optionally the composition comprises (I) encoding (II) and active vitamin D compound); and

(2) a composition (C2) comprising a proliferation inducing amount of (I) encoding (II) encapsulated within liposome (where (II) when expressed is capable of blocking inhibition of proliferation or stimulation of differentiation in vitro of cultured human keratinocytes by PTH(1-34), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), or PTHrP (1-34) or in vivo in mouse skin by stimulating skin cell proliferation or accelerating hair cycle progression or stimulating hair cell growth).

ACTIVITY - Antipsoriatic; dermatological; cytostatic; vulnerary.

No supporting data is given.

MECHANISM OF ACTION - Gene therapy; Inhibits proliferation or enhances differentiation of mammalian skin or hair cells, induces proliferation of mammalian skin or hair cells.

USE - (M1) and (M2) are useful for inhibiting proliferation or enhancing differentiation of mSHC or SHC of a mammal, respectively.

(M1) is useful for inhibiting a hyperproliferative skin disorder such as psoriasis, ichthyosis, eczema, acne, actinic keratosis, or skin cancer, or for inhibiting hair growth or preventing hair regrowth.

(M3) is useful for stimulating cell growth, rejuvenating aged skin, preventing skin wrinkles, treating skin wrinkles, enhancing wound healing, stimulating hair growth, maintaining hair growth, treating or preventing female or male pattern baldness, or treating chemotherapy induced alopecia, and also for stimulating epidermal cell growth or hair follicle cell growth (claimed).

Dwg.0/47

FS CPI

FA AB; DCN

MC CPI: B04-C01A; B04-E03C; B04-J04B; B04-J04B0E; B04-N02; B04-N0200E; B12-M02B; B12-M02F; B12-M05; B14-H01; B14-N17; B14-N17B; B14-N17C; D05-H12A; D05-H17A2; D05-H18; D08-B03; D08-B07; D08-B09; D08-B09A1

TECH UPTX: 20020730

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preferred Method: In (M1) or (M3), (I) is administered as a part of a pharmaceutical composition comprising a carrier such as a liposome. Optionally, (I) is contained within a porous biocompatible matrix. The peptide encoded by (I) has at least 75% sequence identity with the 34 amino acid N-terminal region of hPTH or hPTHrP. (M1) further involves administering to the mSHC, an active vitamin D compound such as calcipotriene, 1,25-dihydroxyvitamin D3, 19-nor-1,25-dihydroxyvitamin D2, or 19-nor-1,25-dihydroxyvitamin D3. The nucleic acid molecule is operably linked to a promoter, and is contained by a plasmid or a viral vector.

In (M2), (I) (encapsulated within a liposome or within a porous biocompatible matrix) and the active vitamin D compound are administered to the individual as part of single pharmaceutical composition, or as part of separate pharmaceutical compositions.

Preferred Composition: In (C1), (I) is optionally contained within a porous biocompatible matrix of at least one of the nucleic acid molecules or active vitamin D compound is encapsulated by liposomes.

ABEX UPTX: 20020730

WIDER DISCLOSURE - Stimulating hair growth administering (I) encoding (II) which when expressed is capable of stimulating hair growth in vitro or in vivo.

**SPECIFIC POLYPEPTIDES** - The peptide encoded by (I) employed in (M1) is PTH (1-34) , PTHrP (1-34) , PTH (1-84) , PTHrP (1-141) , PTHrP (1-139) or PTHrP (1-173) which have fully defined sequences of 34, 35, 84, 141, 139 and 209 amino acids as given in the specification, respectively (claimed).

The peptide encoded by (I) employed in (M3), is PTH (7-34), PTHrP (7-34) , PTH (5-36), PTHrP (5-36), PTH (5-34), PTHrP (5-34), PTH (7-84), PTHrP (7-139), PTHrP (4-141) or PTHrP (7-173) having a fully defined sequence of 28, 29, 32, 32, 30, 30, 78, 133, 135, or 203 amino acids as given in the specification, respectively (claimed).

**SPECIFIC SEQUENCES** - (I) employed in (M1) or (M3) has a fully defined sequence of 255 (hPTH coding sequence), 252 (bovine PTH coding sequence), 426 (hPTHrP coding sequence), 255 (rat PTHrP coding sequence) nucleotides as given in specification, or its fragments (claimed).

**ADMINISTRATION** - In (M1), (I) is administered topically to the mSHC. Optionally, (I) and an active vitamin D compound are administered topically or parenterally.

In (M2), (I) is administered parenterally, and the active vitamin D compound is administered topically or orally (claimed).

Dosage of (I) ranges from 0.001-500 microG/kg/day. Typical daily dosages range from 0.01-100 microG/cm2.

L25 ANSWER 5 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 2001-582276 [65] WPIX  
 DNN N2001-433780 DNC C2001-172698  
 TI Novel isolated matrix metalloproteinase-25 nucleic acid molecule and proteins encoded by them whose inhibition is useful for modulation of hair growth in mammals.  
 DC B04 D16 D21 S03  
 IN FAJARDO, M; MOSS, P; SCHATZMAN, R C; SMITH, R; WANG, K  
 PA (DARW-N) DARWIN MOLECULAR CORP; (FAJA-I) FAJARDO M; (MOSS-I) MOSS P; (SCHA-I) SCHATZMAN R C; (SMIT-I) SMITH R; (WANG-I) WANG K; (SCHA-I) SCHATZMAN R  
 CYC 95  
 PI WO 2001066766 A2 20010913 (200165)\* EN 119 C12N015-55  
 RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ  
 NL OA PT SD SE SL SZ TR TZ UG ZW  
 W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK  
 DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
 LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD  
 SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW  
 AU 2001043455 A 20010917 (200204) C12N015-55  
 US 2002037827 A1 20020328 (200225) A61K031-00  
 ADT WO 2001066766 A2 WO 2001-US7167 20010306; AU 2001043455 A AU 2001-43455  
 20010306; US 2002037827 A1 Provisional US 2000-187196P 20000306, US  
 2001-801196 20010306  
 FDT AU 2001043455 A Based on WO 2001066766  
 PRAI US 2000-187196P 20000306; US 2001-801196 20010306  
 IC ICM A61K031-00; C12N015-55  
 ICS A01K067-00; A61K007-06; A61K031-713; C07H021-04;  
 C07K016-40; C12N005-06; C12N005-10; C12N009-00; C12N009-64;  
 C12N015-11; C12N015-62; C12P021-02; C12Q001-68; G01N033-577  
 AB WO 200166766 A UPAB: 20011108  
 NOVELTY - An isolated matrix metalloproteinase (MMP)-25 nucleic acid molecule (I) comprising a fully defined sequence (NS) of 833 (S1), 1488 (S3) and 1841 (S5) nucleotides as given in specification, nucleotide sequence having 85% identity to NS; complements of NS, or sequences that hybridize to NS, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

(1) a MMP-25 polypeptide (II) comprising a fully defined sequence (PS) of 269 (S2), 466 (S4) or 513 (S6) amino acids as given in specification, an amino acid sequence having 90% identity to PS, amino acid sequence encoded by (I), an amino acid sequence encoded by a nucleotide sequence having 85% identity to (I) or an amino acid sequence encoded by a nucleic acid that hybridizes to (I);

(2) an expression vector (III) comprising (I) operably linked to a expression control sequence;

(3) a host cell transformed or transfected with (III);

(4) preparation of (II);

(5) an antibody (IV) that binds to (II);

(6) a hybridoma which produces (IV);

(7) a fusion protein comprising (II);

(8) a ribozyme that cleaves RNA encoding (II);

(9) an antisense nucleic acid molecule comprising a sequence that is antisense to (I);

(10) inhibiting (M1) catalytic activity of (II) by administering an agent to the cell that inhibits catalytic activity of the polypeptide, provided that the agent inhibits the catalytic activity of the polypeptide to a greater extent than it inhibits the activity of at least one non-type 25 MMP;

(11) inhibiting (M2) expression of (II), by administering to the cell, a vector comprising a nucleic acid molecule which contains a sequence that inhibits expression of (II); and

(12) modulating hair growth in a mammal by applying a composition comprising an inhibitor of MMP provided that the applied composition reduces the catalytic activity of type 25 MMP to a greater extent than it reduces the catalytic activity of a non-type 25 MMP.

ACTIVITY - None given.

MECHANISM OF ACTION - MMP activity or expression inhibitor; hair growth modulator; antisense therapy.

Tests are described but no results given.

USE - (I) is useful for identifying a nucleic acid molecule encoding all or part of MMP by hybridizing (I) to a nucleic acid sample and identifying a sequence that hybridizes in the nucleic acid sample. The identification step involves performing polymerase chain reaction (PCR) to amplify the hybridizing sequence.

(IV) is useful for identifying a type 25 MMP which involves incubating (IV) with a sample containing a protein under conditions which allow the binding of (IV) to the type 25 MMP present in the sample, whereby the binding of the antibody identifies the type 25 MMP.

Furthermore, inhibitors of (II) may be used to modulate hair growth in a mammal (claimed).

Dwg.0/5

FS CPI EPI

FA AB; DCN

MC CPI: B04-C01G; B04-E03E; B04-E06; B04-E07; B04-E08; B04-F0100E; B04-F05; B04-F11; B04-G03; B04-G21; B04-L05C; B04-M01; B11-C08E; B11-C08E5; B12-K04E; B12-K04F; D05-H09; D05-H11A1; **D05-H12A**; D05-H12D2; D05-H12D4; D05-H12E; D05-H14; D05-H15; D05-H17A3; D05-H17C; D05-H18B; D08-B03

EPI: S03-E14H4

TECH UPTX: 20011108

TECHNOLOGY FOCUS - BIOTECHNOLOGY - Preparation: (II) is prepared by standard recombinant techniques (claimed).

Preferred Polypeptide: (II) has a first MMP zinc-binding domain and lacks the second MMP zinc-binding domain. It exhibits or lacks catalytic activity of MMP.

Preferred Vector: (III) is a plasmid vector, phage vector, herpes simplex viral vector, adenoviral vector, adenovirus-associated viral vector, or retroviral vector.

Preferred Antibody: (IV) is a monoclonal antibody.

Preferred Method: In (M2), a nucleic acid molecule which contains the sequence that inhibits expression of (II), encodes a non-functional variant of MMP which has:

- (i) an amino acid sequence as described above, or
- (ii) a polypeptide comprising first MMP zinc-binding domain with the proviso that the polypeptide lacks a second MMP Zn-binding domain, or
- (iii) an amino acid sequence encoded by a nucleic acid molecule that hybridizes under conditions of high stringency to (I).

Preferably, the nucleic acid molecule encodes a ribozyme that cleaves RNA encoding MMP-25 polypeptide or contains a sequence that is antisense to a portion of RNA encoding MMP-25 polypeptide.

ABEX

UPTX: 20011108

WIDER DISCLOSURE - Also disclosed as new are the following:

- (1) nucleic acid fragment or oligonucleotide encoding at least 8 contiguous amino acids of PS;
- (2) vectors comprising the antisense molecules or ribozymes and host cells comprising these vectors;
- (3) a nucleic acid molecule comprising a sequence that encodes a peptide of 27 amino acids in length, where the peptide is a consensus sequence for a Zn-binding domain of MMP; and
- (4) identifying a nucleic acid encoding all or part of MMP by identifying a sequence encoded by the above mentioned consensus sequence and cloning a sequence containing the identified sequence from a cDNA library.

ADMINISTRATION - Administration is topical.

Dosages is 10-3000 microg/cm<sup>2</sup>.

EXAMPLE - A first matrix metalloproteinase (MMP-25(l)) was identified. The polynucleotide encodes a protein comprising the conserved peptide sequences LVAAHELGHXLGLXHSXXXXAXMSSSY and HGDXXPFDGXXXXLAHAFXPGXGGDXHPDX GEXWT. These conserved peptide sequences represent a consensus for MMP polypeptides as determined by aligning protein sequences of several MMP family members using a multiple sequence alignment program. The first MMP sequence identified comprises 833 bp. To obtain a full-length cDNA sequence for the novel MMP, a mammary gland cDNA expression library was screened by amplification using rapid amplification of cDNA ends (RACE) reactions with unique sequence primers deduced from the 833 bp sequence in combination with primers that bind to 5' and 3' vector sequences adjacent to the ends of cloned inserts. The vector primer AP1 was used with one of the following primers from the candidate 833 bp sequence to amplify the 5' sequences, TGATATCATAATAGATCCTCCATAGGTGCC and TTCCTTAGGCAGACCTCCATAGATGGACTGG. The vector primer AP2 was used with one of the following primers from the candidate 833 bp sequence to amplify the 3' sequences, CCTAAGGAACCTGCTAAGCCAAAGGAA and CCGCAGAGAAGTAATGTTCTTTAAA. Using the above method, a novel sequence of 1833 bp in length with an open reading frame of 1530 bp was identified. A second novel metalloproteinase sequence (MMP-23(s)) was also identified by cDNA library screening using RACE reactions. The nucleotide sequence encoding MMP-25(s) has a fully defined sequence of 1488 nucleotides and encodes a polypeptide having a fully defined sequence 466 amino acids as given in specification. The nucleotide sequence of MMP-25(s) was identical to the sequence for MMP-25(l) except in having a deletion of 129 nucleotides corresponding to 43 amino acids. The deleted sequence in the shorter version of MMP-25 was unique among metalloproteinases: while the encoded protein contains the first Zn-binding domain, it lacks the second Zn/Ca-binding domain typical for other members of the matrix metalloproteinase family. In situ hybridization results revealed that MMP-25 was expressed in the inner root

sheath layer of the hair follicle. The cell layer within the inner root sheath, the Henle layer was further defined as a particular cell type for MMP25 mRNA expression in skin. The particular localization of MMP-25 expression in inner root sheath of hair follicles indicates that control of the expression of the MMP-25 sub-family of metalloproteinases was involved in the regulation of hair growth. Chromosomal location for human MMP-25 showed that it maps to chromosome 11q22, a region where several other MMPs including MMP1, MMP3, MMP7, MMP8, MMP10, MMP12 and MMP13, have been previously mapped.

L25 ANSWER 6 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 2001-229036 [24] WPIX

DNC C2001-068633

TI Hair growth inhibitor useful as external preparation for inhibiting hair growth on legs and under armpits contains neutral endopeptidase inhibitor as active ingredient.

DC B05 D21

PA (KAOS) KAO CORP

CYC 1

PI JP 2000351716 A 20001219 (200124)\* 8 A61K007-06 <--

ADT JP 2000351716 A JP 1999-271970 19990927

PRAI JP 1999-97504 19990405

IC ICM A61K007-06

ICS A61K045-00; A61P043-00

ICA A61K031-19; A61K031-215

AB JP2000351716 A UPAB: 20010502

NOVELTY - Hair growth inhibitor contains neutral endopeptidase inhibitor as active ingredient.

USE - As external preparation for inhibiting hair growth e.g. on legs and under armpits so avoiding physical depilation and shaving.

Hair growth inhibition effect of a compound of formula (Ia) was evaluated in five 6 week old C3H mice. 100 micro l of the sample dissolved in 80 % ethanol was applied for 4 weeks and a control mouse was applied with 80 % ethanol alone. The hair growth inhibition was found to be excellent.

Dwg.0/0

FS CPI

FA AB; GI; DCN

MC CPI: B10-D03; B14-D07C; B14-R01; D08-B07

TECH UPTX: 20010502

TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Inhibitor: 7 neutral endopeptidase inhibitor are disclosed, especially malonamide derivative of formula (I) is used.

R1 = H, alkyl, alkenyl or aralkyl;

R2 = H or optionally substituted alkyl, alkenyl or aralkyl;

R3 = heterocyclic ring having NH group, alkyl, alkenyl or joined to R4;

R4 = H or substituted alkyl, alkenyl, aralkyl or joined to R3;

R5 = OH, alkoxy, alkenyloxy, or amino acid residue; and

n = 0-5.

L25 ANSWER 7 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 2000-545818 [50] WPIX

DNC C2000-162757

TI Hair growth inhibitor comprises steroids, specific roots, tomato and hair growth inhibitor containing extract obtained from specific crude drug.

DC B01 B04 D21 E15

PA (LIOY) LION CORP

CYC 1

PI JP 2000191459 A 20000711 (200050)\* 6 A61K007-06 <--

ADT JP 2000191459 A JP 1998-369605 19981225

PRAI JP 1998-369605 19981225  
IC ICM A61K007-06  
ICS A61K031-566; A61K031-57; A61K035-78; A61P043-00  
AB JP2000191459 A UPAB: 20001010  
NOVELTY - Hair growth inhibitor comprises steroids such as cyproterone, 5 alpha -androstene-3 alpha ,17 beta -diol, medoroxypregnosterone, norethisterone, mestanolone and/or derivatives, Scutellaria root, Lithospermum root, tomato and a hair growth inhibitor containing extract obtained from a crude drug such as Hedera helix.  
DETAILED DESCRIPTION - An INDEPENDENT CLAIM is also included for a cosmetic containing the hair growth inhibitor.  
USE - Used as a hair growth inhibitor.  
ADVANTAGE - The inhibitor has excellent inhibition of hair growth.  
A test was performed to observe the hair growth inhibitory effect. A steroid was dissolved in a solvent to obtain a concentration of 0.5 weight% of sample. Hair of a mouse of 49 days old was depleted without damaging the skin. The mouse was applied with 0.1 ml of sample, once daily for two days. A control was simultaneously prepared by applying the solvent alone. The amount of hair growth was computed by comparing with the control. An excellent hair growth inhibitory effect was observed.  
Dwg.0/0  
FS CPI  
FA AB; DCN  
MC CPI: B01-C05; B01-D02; B04-A08C2; B04-A09D; B04-A10; B04-A10F; D08-B03; E01  
ABEX UPTX: 20001010  
EXAMPLE - A hair growth inhibition cream was prepared by using (in weight%) Cyproterone acetate (0.05), stearic acid (2), hydrogenated lanolin (4), squalane (9), octyl dodecanol (10), 1,3-butylene glycol (4), glycerol (3), polyoxyethylene (POE) (25), cetyl ethyl (3), glyceryl monostearate (2), ethylparaben (0.1), butylparaben (0.1) and purified water (remaining) to obtain a cream (100).  
L25 ANSWER 8 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN  
AN 1997-448705 [41] WPIX  
DNC C1997-143119  
TI Removing hair from selected skin area giving longer lasting result - by applying liposome containing photosensitizer, removing liposome and applying light to cause photosensitizer to damage hair follicles.  
DC B02 D21 E19  
IN BEN-HUR, E; CHAN, W; ZUK, M M  
PA (NYBL-N) NEW YORK BLOOD CENT INC; (NEWB-N) NEW BLOOD CENT INC  
CYC 72  
PI WO 9732046 A1 19970904 (199741)\* EN 19 C14C001-06  
RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG  
W: AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN  
AU 9721359 A 19970916 (199803) C14C001-06  
EP 883695 A1 19981216 (199903) EN C14C001-06  
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
JP 2000506140 W 20000523 (200033) 17 A61K007-155  
US 6143287 A 20001107 (200059) A61K007-06 <--  
EP 883695 B1 20010606 (200133) EN C14C001-06  
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE  
DE 69705111 E 20010712 (200147) C14C001-06  
US 6365145 B1 20020402 (200226) A61K007-06 <--  
ADT WO 9732046 A1 WO 1997-US2851 19970224; AU 9721359 A AU 1997-21359 19970224; EP 883695 A1 EP 1997-906751 19970224, WO 1997-US2851 19970224;

JP 2000506140 W JP 1997-531047 19970224, WO 1997-US2851 19970224; US 6143287 A US 1996-607526 19960227; EP 883695 B1 EP 1997-906751 19970224, WO 1997-US2851 19970224; DE 69705111 E DE 1997-605111 19970224, EP 1997-906751 19970224, WO 1997-US2851 19970224; US 6365145 B1 Cont of US 1996-607526 19960227, US 2000-587406 20000605

FDT AU 9721359 A Based on WO 9732046; EP 883695 A1 Based on WO 9732046; JP 2000506140 W Based on WO 9732046; EP 883695 B1 Based on WO 9732046; DE 69705111 E Based on EP 883695, Based on WO 9732046; US 6365145 B1 Cont of US 6143287

PRAI US 1996-607526 19960227; US 2000-587406 20000605

REP US 5198470; US 5277913

IC ICM **A61K007-06**; A61K007-155; C14C001-06

ICS A61K007-15; A61K009-127; A61K045-00; A61P017-00

AB WO 9732046 A UPAB: 19971013

A method for removing hair from a selected area of skin comprises: (a) applying a liposome composition comprising a photosensitiser to the selected skin area so that the composition is introduced into the hair follicle ducts of the skin area. The photosensitiser is present in an amount effective to undergo a reaction and damage the hair follicles upon application to the skin area of light of appropriate wave length, energy and duration to penetrate the skin and activate the photosensitiser; (b) removing from the skin area substantially all the liposome composition which is not introduced into the follicle ducts; and (c) applying the light to the skin area to penetrate the skin and cause the photosensitiser to undergo reaction and damage the hair follicles.

Also claimed is the liposome composition used in the method.

USE - The composition and the method are useful for removing hair from areas of skin, such as mustache, from hands and legs etc.

ADVANTAGE - The method is not time consuming, painful and damaging to the skin. The method results in hair removal which is long lasting, and more permanent than conventional methods.

Dwg.0/6

FS CPI

FA AB; DCN

MC CPI: B04-B01B; B05-A01B; B05-A02; B05-B01P; **B06-D18**; B12-M11F; **D08-B07**; E22-C02; E23; E25-E02

L25 ANSWER 9 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN **1997-310350** [28] WPIX

DNC C1997-099806

TI Reducing mammalian hair growth - by suppression of conversion of glucose to acetyl coenzyme A, especially for treatment of hirsutism in women.

DC B05 D21 E19

IN AHLUWALIA, G; HENRY, J; SHANDER, D

PA (GILL) GILLETTE CO; (HAND-I) HANDELMAN J H; (AHLU-I) AHLUWALIA G; (HENR-I) HENRY J; (SHAN-I) SHANDER D

CYC 76

PI WO 9719673 A2 19970605 (199728)\* EN 17 A61K007-06 <--  
RW: AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD  
SE SZ UG

W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE  
HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX  
NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

US 5652273 A 19970729 (199736) 6 A61K031-13

ZA 9609781 A 19970827 (199740) 17 A61K000-00

AU 9710865 A 19970619 (199741) A61K007-06 <--

WO 9719673 A3 19971002 (199814) A61K007-06 <--

EP 863741 A2 19980916 (199841) EN A61K007-06 <--

R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

US 5824665 A 19981020 (199849) A61K031-13

BR 9611756	A	19990406 (199920)		A61K007-06	<--
JP 2000501098	W	20000202 (200017)	21	A61K007-06	<--
MX 9804296	A1	19980901 (200017)		A61K007-06	<--
AU 728886	B	20010118 (200109)		A61K007-06	<--
US 6218435	B1	20010417 (200123)		A61K031-13	
CA 2237780	C	20020129 (200211)	EN	A61K007-06	<--
MX 202316	B	20010613 (200235)		A61K031-13	
EP 1352627	A2	20031015 (200368)	EN	A61K007-06	<--

R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

ADT WO 9719673 A2 WO 1996-US19102 19961125; US 5652273 A US 1995-565728 19951130; ZA 9609781 A ZA 1996-9781 19961121; AU 9710865 A AU 1997-10865 19961125; WO 9719673 A3 WO 1996-US19102 19961125; EP 863741 A2 EP 1996-940921 19961125, WO 1996-US19102 19961125; US 5824665 A Div ex US 1995-565728 19951130, US 1997-842054 19970423; BR 9611756 A BR 1996-11756 19961125, WO 1996-US19102 19961125; JP 2000501098 W WO 1996-US19102 19961125, JP 1997-520706 19961125; MX 9804296 A1 MX 1998-4296 19980529; AU 728886 B AU 1997-10865 19961125; US 6218435 B1 Div ex US 1995-565728 19951130, Div ex US 1997-842054 19970423, US 1998-118946 19980717; CA 2237780 C CA 1996-2237780 19961125, WO 1996-US19102 19961125; MX 202316 B MX 1998-4296 19980529; EP 1352627 A2 Div ex EP 1996-940921 19961125, EP 2003-10707 19961125

FDT AU 9710865 A Based on WO 9719673; EP 863741 A2 Based on WO 9719673; US 5824665 A Div ex US 5652273; BR 9611756 A Based on WO 9719673; JP 2000501098 W Based on WO 9719673; AU 728886 B Previous Publ. AU 9710865, Based on WO 9719673; US 6218435 B1 Div ex US 5652273, Div ex US 5824665; CA 2237780 C Based on WO 9719673; EP 1352627 A2 Div ex EP 863741

PRAI US 1995-565728 19951130; US 1997-842054 19970423;  
US 1998-118946 19980717

REP EP 711541; WO 9104058

IC ICM A61K000-00; **A61K007-06**; A61K031-13

ICS A61K031-191; A61K031-275; A61K031-35; A61K031-47; A61K031-661;  
A61K031-70; A61K031-7008; A61K045-00; A61P017-00

AB WO 9719673 A UPAB: 19970709

Reducing mammalian hair growth comprises: (a) selecting an area of skin from which reduced hair growth is desired, and (b) applying a dermatologically acceptable composition comprising a suppressor of the metabolic pathway for the conversion of glucose to acetyl-CoA to reduce hair growth.

Also claimed is a composition for use for the reduction and inhibition of hair growth which comprises a suppressor of the metabolic pathway for the conversion of glucose to acetyl-CoA and a non-toxic vehicle or carrier.

The suppressor is: (a) an inhibitor of hexokinase selected from 6-amino-6-deoxy-glucose, N-acetyl- beta -D-mannosamine, D-mannosamine or N- alpha -(p-tosyl)-L-lysine chloromethyl ketone; (b) an inhibitor of phosphofructokinase selected from phosphoglycerate, quinone methide (taxodone or taxodione), alpha -methylene lactone (euparotin acetate, eupacunin or vernolepin), agaric acid, quinaldic acid, 5'-p-fluorosulphonyl benzoyl adenosine; and (c) an inhibitor of aldose selected from 5-keto-D-fructose and 5-keto-D-fructose- 1,6-bisphosphate.

USE - The composition can be used on the face of a human, preferably of a woman suffering from hirsutism (claimed). The composition can be applied to the cheek, neck, upper lip, chin, legs, arms, torso or armpits at least twice/day for at least 3 months to achieve a perceived reduction in hair growth. The composition should be applied at 10-3000 mu g/cm2 skin.

Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: **B04-B03A**; B05-B01P; B07-A02; B10-A06; B14-D02A;

D08-B07; E07-A02; E07-A02F; E07-A02H

ABEQ US 5652273 A UPAB: 19970909

Reducing mammalian hair growth comprises

selecting an area of skin from which reduced hair growth is desired;  
and applying to the area of skin a dermatologically acceptable composition  
comprising an inhibitor of hexokinase in an amount effective to reduce  
hair growth.

Dwg.0/1

L25 ANSWER 10 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 1995-328081 [42] WPIX

DNC C1995-145519

TI Inhibiting hair growth in mammals - using ornithine amino transferase  
inhibitor, especially for cosmetic inhibition of facial hair.

DC B05 D16 E14 E16

IN THOMPSON, L W; WALLACE, H M; WISLER, M M; WU, J; FUNKHOUSER, M G; SHANDER,  
DPA (BAKO) BAKER HUGHES INC; (HAND-I) HANDELMAN J H; (FUNK-I) FUNKHOUSER M G;  
(SHAN-I) SHANDER D

CYC 65

PI WO 9524181 A1 19950914 (199542)\* EN 15 A61K007-06 <--  
RW: AT BE CH DE DK ES FR GB GR IE IT KE LU MC MW NL OA PT SD SE SZ UG  
W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG  
KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE  
SG SI SK TJ TM TT UA UG US UZ VN

AU 9521172 A 19950925 (199601) A61K007-06 &lt;--

US 5474763 A 19951212 (199604) 3 A61K007-06 &lt;--

ZA 9502031 A 19960228 (199614) 13 A61K000-00

EP 754024 A1 19970122 (199709) EN A61K007-06 &lt;--

R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

JP 09510210 W 19971014 (199751) 13 A61K007-06 &lt;--

MX 9603923 A1 19970401 (199821) A61K007-06 &lt;--

EP 754024 B1 19981028 (199847) EN A61K007-06 &lt;--

R: AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

AU 696879 B 19980924 (199850) A61K007-06 &lt;--

DE 69505651 E 19981203 (199903) A61K007-06 &lt;--

ES 2122570 T3 19981216 (199906) A61K007-06 &lt;--

CA 2184170 C 19991207 (200017) EN A61K007-06 &lt;--

MX 194862 B 20000111 (200115) A61K007-006

ADT WO 9524181 A1 WO 1995-US2915 19950308; AU 9521172 A AU 1995-21172

19950308; US 5474763 A US 1994-212012 19940311; ZA 9502031 A ZA 1995-2031

19950310; EP 754024 A1 EP 1995-913991 19950308; WO 1995-US2915 19950308;

JP 09510210 W JP 1995-523629 19950308; WO 1995-US2915 19950308; MX 9603923

A1 MX 1996-3923 19960906; EP 754024 B1 EP 1995-913991 19950308; WO

1995-US2915 19950308; AU 696879 B AU 1995-21172 19950308; DE 69505651 E DE

1995-605651 19950308; EP 1995-913991 19950308; WO 1995-US2915 19950308; ES

2122570 T3 EP 1995-913991 19950308; CA 2184170 C CA 1995-2184170 19950308;

WO 1995-US2915 19950308; MX 194862 B MX 1996-3923 19960906

FDT AU 9521172 A Based on WO 9524181; EP 754024 A1 Based on WO 9524181; JP

09510210 W Based on WO 9524181; EP 754024 B1 Based on WO 9524181; AU

696879 B Previous Publ. AU 9521172, Based on WO 9524181; DE 69505651 E

Based on EP 754024, Based on WO 9524181; ES 2122570 T3 Based on EP 754024;

CA 2184170 C Based on WO 9524181

PRAI US 1994-212012 19940311; US 1994-212194 19940311;

US 1994-212257 19940314; US 1994-212269 19940314;

US 1994-214343 19940314; US 1994-214916 19940314

REP WO 8602269; WO 9421216; WO 9421217

IC ICM A61K000-00; A61K007-006; A61K007-06

ICS A61K007-15; A61K007-155; A61K031-19

AB WO 9524181 A UPAB: 19951026

Mammalian hair growth is inhibited by applying to a selected area of the skin a compsn. containing an inhibitor (I) of ornithine aminotransferase (OAT).

Also new are compsns. containing (I) and a dermatological vehicle or carrier. Compsns. are partic. used in cosmetics to inhibit hair growth on the face. (I) partic. inhibit androgen stimulates hair growth, e.g. in cases of female hirsutism.

(I) is pref. 6-fluoro-2,5-diamino hexanoic acid; (S)-2-amino-4-amino oxy-butyric acid or 3-amino-2,3-dihydro benzoic acid (which are irreversible inhibitors).

These contain 1-30% (I) plus a spreadable vehicle or carrier. (I) is applied at 100-3000 mug/cm<sup>2</sup> of skin, typically once or twice a day for at least 3 months. The treatment causes a reduction in growth of at least 30 (best at least 70)% in the Golden Syrian hamster assay.

Dwg.0/0

FS CPI  
FA AB; DCN  
MC CPI: B04-C03B; B10-A11B; B10-A18; B10-B01B; B10-B02E; B10-E04B; B10-E04C; B12-M02F; B14-D02; B14-D06; B14-N17; D05-C03; D08-B03; E10-B01C; E10-B02A

ABEQ US 5474763 A UPAB: 19960129

A method of reducing mammalian hair growth which comprises selecting an area of skin of a mammal from which hair is growing and from which reduced hair growth is desired; and

applying to said area of skin of a mammal from which hair is growing and from which reduced hair growth is desired an inhibitor of ornithine amino-transferase in an amount effective to reduce hair growth.

Dwg.0/0

L25 ANSWER 11 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 1993-167280 [20] WPIX

CR 1995-350220 [45]

DNC C1993-074552

TI Reduction of hair growth and altering character - by topical application of L-asparagine synthetase inhibitor e.g. guanidino-succinic acid.

DC B05 D21 E19 P14

IN AHLUWALIA, G S; HANDELMAN, J H

PA (HAND-I) HANDELMAN J H; (GILL) GILLETTE CO

CYC 39

PI WO 9308687 A1 19930513 (199320)\* EN 9 A01N037-10  
RW: AT BE CH DE DK ES FR GB GR IE IT LU MC NI, OA SE  
W: AT AU BB BG BR CA CH CE DE EE FI FR GB GR IE IT LU MC NI, OA SE  
NL NO PL RO RU SI JP KP KR LK LU MG MN MW

AU 9230627 A 19930 A01N037-10

EP 612211 A1 19940 A01N037-10

R: AT BE CH DE DK ES

JP 07504646 W 19950! A61K031-19 <--

EP 612211 A4 19941: A01N037-10

AU 670554 B 19960: A61K031-19 <--

CA 2122002 C 199712 A61K007-06 <--

EP 612211 B1 200206 A01N037-10

R: AT BE CH DE DK ES

DE 69232628 E 20020711 (200253) A01N037-10

ES 2173874 T3 20021101 (200279) A01N037-10

ADT WO 9308687 A1 WO 1992-US9438 19921104; AU 9230627 A AU 1992-30627 19921104; EP 612211 A1 EP 1992-924244 19921104, WO 1992-US9438 19921104; JP 07504646 W WO 1992-US9438 19921104, JP 1993-508679 19921104; EP 612211 A4 EP 1992-924244 ; AU 670554 B AU 1992-30627 19921104; CA 2122002 C CA 1992-2122002 19921104; EP 612211 B1 EP 1992-924244 19921104, WO 1992-US9438 19921104; DE 69232628 E DE 1992-632628 19921104, EP

1992-924244 19921104, WO 1992-US9438 19921104; ES 2173874 T3 EP .  
 1992-924244 19921104

FDT AU 9230627 A Based on WO 9308687; EP 612211 A1 Based on WO 9308687; JP 07504646 W Based on WO 9308687; AU 670554 B Previous Publ. AU 9230627, Based on WO 9308687; EP 612211 B1 Based on WO 9308687; DE 69232628 E Based on EP 612211, Based on WO 9308687; ES 2173874 T3 Based on EP 612211

PRAI US 1991-788168 19911105

REP US 4435419; 2.Jnl.Ref

IC ICM A01N037-10; A61K007-06; A61K031-19  
 ICS A01K067-00; A01N037-12; A61K031-195

AB WO 9308687 A UPAB: 20021209  
 Reduction of rate and altering character of mammalian hair growth, comprising application of a compsn. containing an organic inhibitor of L-asparagine synthetase, is new.  
 Inhibitors are pref. guandinosuccinic acid, oxaloacetic acid, cysteinesulphinic acid, diethyl aminomalonate, or ethacrynic acid.  
 USE - The inhibitor is non-irritant, as inorganic materials are. It affects partic. androgen stimulated hair growth. Compsns. comprise 0.1-30% inhibitor and opt. a penetration enhancer, and the application rate is 10-7500 mcg/sq.cm. of skin  
 Dwg.O/O  
 Dwg.O/O

FS CPI GMPI

FA AB; DCN

MC CPI: B10-A17; B12-G01B6; B12-L05; D08-B03; E10-A09C; E10-A17; E10-B02D5; E10-C02F; E10-C03

L25 ANSWER 12 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 1993-153849 [19] WPIX

DNC C1993-068623

TI Topical compsn. for reducing, retarding or eliminating hair growth - comprising inhibitor of glutamine metabolism in mammalian skin or hair and cosmetically acceptable vehicle.

DC B05 D21 E19 E37

IN KEALEY, T; WESTGATE, G E; WILLIAMS, R; KEALEY, G T E; KEALEY, G T; KEALY, G T E

PA (UNIL) UNILEVER PLC; (UNIL) UNILEVER NV; (UNIL) UNILEVER LTD; (CHEO) CHESEBROUGH PONDS USA CO

CYC 24

PI EP 532219 A2 19930317 (199319)\* EN 19 A61K007-48  
 R: AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE

AU 9222119	A	19930311 (199319)		A61K007-155
BR 9203450	A	19930406 (199319)		A61K007-155
CA 2077144	A	19930305 (199320)		A61K007-06 <--
JP 05194163	A	19930803 (199335)	15	A61K007-155
TW 221027	A	19940211 (199414)		A61K031-19 <--
ZA 9206719	A	19940525 (199423)	45	A61K000-00
US 5378455	A	19950103 (199507)	11	A61K007-06 <--
EP 532219	A3	19931118 (199512)		A61K007-48
AU 666123	B	19960201 (199612)		A61K007-155
EP 532219	B1	19960508 (199623)	EN 23	A61K007-06 <--
	R:	AT BE CH DE DK ES FR GB GR IE IT LI NL PT SE		
DE 69210515	E	19960613 (199629)		A61K007-06 <--
JP 2525315	B2	19960821 (199638)	15	A61K007-155
CA 2077144	C	19971118 (199807)		A61K007-06 <--
KR 9615950	B1	19961125 (199930)		A61K007-06 <--
PH 31037	A	19971229 (200255)		A61K007-06 <--

ADT EP 532219 A2 EP 1992-307961 19920902; AU 9222119 A AU 1992-22119 19920904; BR 9203450 A BR 1992-3450 19920903; CA 2077144 A CA 1992-2077144 19920828; JP 05194163 A JP 1992-233880 19920901; TW 221027 A TW 1992-108349

19921020; ZA 9206719 A ZA 1992-6719 19920904; US 5378455 A Cont of US  
1992-937795 19920828, US 1993-173261 19931227; EP 532219 A3 EP 1992-307961  
19920902; AU 666123 B AU 1992-22119 19920904; EP 532219 B1 EP 1992-307961  
19920902; DE 69210515 E DE 1992-610515 19920902, EP 1992-307961 19920902;  
JP 2525315 B2 JP 1992-233880 19920901; CA 2077144 C CA 1992-2077144  
19920828; KR 9615950 B1 KR 1992-16069 19920904; PH 31037 A PH 1992-44878  
19920831

FDT AU 666123 B Previous Publ. AU 9222119; DE 69210515 E Based on EP 532219;  
JP 2525315 B2 Previous Publ. JP 05194163

PRAI GB 1991-18866 19910904

REP No-SR.Pub; WO 8602269; WO 8808295

IC ICM A61K000-00; **A61K007-06**; A61K007-155; A61K007-48;  
**A61K031-19**  
ICS A61K007-16

AB EP 532219 A UPAB: 19970502  
Compsn. suitable for topical application to mammalian skin for reducing,  
retarding or eliminating hair growth. The compsn comprises: (a) an  
effective amount of an inhibitor of glutamine metabolism in mammalian skin  
or hair; and (b) a cosmetically acceptable vehicle for the inhibitor. The  
inhibitor is an agent for inhibiting at least one enzyme involved in the  
conversion of glutamine to lactate in mammalian skin or hair.  
USE - Compsns. may be used: either to prevent or retard regrowth  
after hair removal by a conventional method; or to reduce the rate of hair  
growth, e.g. in a beard, without consequential hair loss.  
Dwg.0/0

FS CPI

FA AB; DCN

MC CPI: B05-A03A; B05-A03B; B07-A01; B10-C02; B10-C04E; B12-G01B1; B12-G01B3;  
B12-L05; **D08-B07**; E05-L03B; E07-A01; E10-A16; E10-C02D;  
E10-C02F; E35-N

ABEQ US 5378455 A UPAB: 19950223  
Topical compsn. for application to mammalian skin comprises: (a) an  
inhibitor of glutamine metabolism where one or more enzymes involves in  
conversion of glutamine to lactate are present; and (b) a cosmetic  
vehicle. (a) comprises glutamine, glutamate dehydrogenase,  
alpha-ketoglutarate decarboxylase, succinyl CoA synthetase, succinate  
dehydrogenase, fumarase, malate dehydrogenase and/or malic enzyme.  
USE - Used for reducing, retarding or eliminating hair growth by  
topical application of a water-in-oil emulsion.  
Dwg.0/1

ABEQ EP 532219 B UPAB: 19960610  
A cosmetic method for reducing, retarding or eliminating mammalian hair  
growth, which comprises topically applying to the skin a composition  
comprising: (i) an effective amount of an inhibitor of glutamine  
metabolism in mammalian skin or hair; and (ii) a cosmetically acceptable  
vehicle for the inhibitor.  
Dwg.0/1

L25 ANSWER 13 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN **1992-096580** [12] WPIX

DNC C1992-044798

TI Reduction of mammalian hair growth rate - by topical application of  
S-adenosyl methionine decarboxylase inhibitor and opt. ornithine  
decarboxylase inhibitor, and compsn. containing these.

DC B02 B05

IN AHLUWALIA, G S; HARRINGTON, E F; SHANDER, D; HANDELMAN, J H; HARRINGTON, F  
E

PA (HAND-I) HANDELMAN J H; (GILL) GILLETTE CO; (SHAN-I) SHANDER D

CYC 33

PI WO 9203140 A 19920305 (199212)\* 11

RW: AT CH DE ES GB GR LU NL SE

W: AT AU BB BG BR CA CS DE GB JP KP KR LK LU MG MN MW NL NO PL RO SD  
SE SU US

AU 9187232 A 19920317 (199226) A61K031-70  
 US 5132293 A 19920721 (199232) 4 A61K031-70  
 EP 543949 A1 19930602 (199322) EN A61K031-70

R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE

JP 06500335 W 19940113 (199407) 6 A61K007-155  
 AU 657710 B 19950323 (199519) A61K031-70  
 EP 543949 A4 19930804 (199527)  
 EP 543949 B1 19971022 (199747) EN 7 A61K031-70

R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE

DE 69128034 E 19971127 (199802) A61K031-70  
 ES 2109949 T3 19980201 (199811) A61K031-70  
 CA 2088909 C 20020319 (200228) EN A61K031-70  
 JP 3299961 B2 20020708 (200247) 5 A61K007-155

ADT WO 9203140 A WO 1991-US5721 19910812; AU 9187232 A AU 1991-87232 19910812,  
 WO 1991-US5721 19910812; US 5132293 A Cont of US 1990-567018 19900814, US  
 1991-784650 19911028; EP 543949 A1 EP 1991-918121 19910812, WO 1991-US5721  
 19910812; JP 06500335 W JP 1991-516613 19910812, WO 1991-US5721 19910812;  
 AU 657710 B AU 1991-87232 19910812; EP 543949 A4 EP 1991-918121 ;  
 EP 543949 B1 EP 1991-918121 19910812, WO 1991-US5721 19910812; DE 69128034  
 E DE 1991-628034 19910812, EP 1991-918121 19910812, WO 1991-US5721  
 19910812; ES 2109949 T3 EP 1991-918121 19910812; CA 2088909 C CA  
 1991-2088909 19910812, WO 1991-US5721 19910812; JP 3299961 B2 JP  
 1991-516613 19910812, WO 1991-US5721 19910812

FDT AU 9187232 A Based on WO 9203140; EP 543949 A1 Based on WO 9203140; JP  
 06500335 W Based on WO 9203140; AU 657710 B Previous Publ. AU 9187232,  
 Based on WO 9203140; EP 543949 B1 Based on WO 9203140; DE 69128034 E Based  
 on EP 543949, Based on WO 9203140; ES 2109949 T3 Based on EP 543949; CA  
 2088909 C Based on WO 9203140; JP 3299961 B2 Previous Publ. JP 06500335,  
 Based on WO 9203140

PRAI US 1990-567018 19900814

REP 5.Jnl.Ref; US 4720489; 1.Jnl.Ref; 14Jnl.Ref

IC ICM A61K007-155; A61K031-70

ICS A61K007-06; A61K031-00; A61K031-13; A61K031-15;  
 A61K031-155; A61K031-16; A61K031-195

AB WO 9203140 A UPAB: 19931006

To reduce the rate and alter the character of mammalian hair growth there  
 is applied to the skin a compsn. containing an inhibitor of S-adenosyl  
 methionine decarboxylase (I) and opt. containing an ornithine decarboxylase  
 inhibitor (II). A topical compsn. for this use comprises a suitable  
 carrier and 0.1-50% based on the total compsn. weight of (I) and 0.1-20% of  
 (II). (I) is methylglyoxal bis(guanylhydrazone), diethyl glyoxal  
 bis(quanylhydrazone) or 5'-deoxy-5'-(N-methyl-N-(2-aminooxy-ethyl)  
 -aminoadenosine (MAOEA). (II) is 2-difluoromethyl -ornithine (DFMO),  
 alpha-ethynyl-ornithine, 6-heptyne-2,4-diamine or 2-methyl-6-heptyne-2,5-  
 diamine.

ADVANTAGE - (I) and (II) act synergistically. (I) are generally  
 applied at a rate of 1-5000 micro grams per sq. cm of skin and (II) at a  
 rate of 1-2000 micrograms. Relative proportions of (I) and (II) in  
 combination are pref. in the weight range 1:10 to 10:1.

0/0

FS CPI

FA AB; DCN

MC CPI: B04-B03A; B10-A17; B10-B01B; B12-C09; B12-G01B4; B12-L05

ABEQ US 5132293 A UPAB: 19931006

A new process for the redn. of the rate and altering the character of hair  
 growth comprises admin. to the skin of a compsn. contg. an inhibitor of  
 S-adenosylmethionine decarboxylase, pref. with an ornithine decarboxylase

inhibitor.

The former may be methylglyoxal-bis-(guanylhyazone) or the corresp. diethylglyoxal cpd. or 5'-deoxy-5'-(N-methyl-N)-aminoadenosine and the latter may be 2-(difluoromethyl)-ornithine, alpha-ethynylornithine, 6-heptyl-2,5-diamine or 2-methyl-6-heptyne-2,5-diamine.

Pref. the former is at concn. 1-5000 and the latter 1-2000 mcg/cm2 of skin.

ADVANTAGE - The compsn. exhibits synergistic action.

0/0

ABEQ EP 543949 A UPAB: 19931115

To reduce the rate and alter the character of mammalian hair growth there is applied to the skin a compsn. contg. an inhibitor of S-adenosyl methionine decarboxylase (I) and opt. contg. an ornithine decarboxylase inhibitor (II). A topical compsn. for this use comprises a suitable carrier and 0.1-50% based on the total compsn. wt. of (I) and 0.1-20% of (II).

(I) is methylglyoxal bis(guanylhyazone), diethyl glyoxal bis(guanylhyazone), diethyl glyoxal bis(guanylhyazone) or 5'-deoxy-5'-(N-methyl-N-(2-aminooxy-ethyl)-aminoadenosine (MAOEA). (II) is 2-difluoromethyl-ornithine (DFMO), alpha-ethynyl-ornithine 6-heptyne-2,4-diamine or 2-methyl-6-heptyne-2,5-diamine.

ADVANTAGE - (I) and (II) act synergistically. (I) are generally applied at a rate of 1-500 micro grams per sq.cm. of skin and (II) at a rate of 1-2000 micrograms. Relative proportions of (I) and (II) in combination are pref. in the wt. range 1:10-10:1.

ABEQ EP 543949 B UPAB: 19971125

The cosmetic process of reducing the rate and altering the character of mammalian hair growth which comprises the step of applying to the skin a composition containing an inhibitor of S-adenosylmethionine decarboxylase. Dwg.0/0

L25 ANSWER 14 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 1986-119079 [18] WPIX

DNC C1986-050768

TI Hair growth modification - by topical application of a material inhibiting the action of ornithine decarboxylase.

DC B01 B05 D21

IN SHANDER, D

PA (HAND-I) HANDELMAN J H; (SHAN-I) SHANDER D

CYC 21

PI WO 8602269 A 19860424 (198618)\* EN 18

RW: AT BE CH DE FR GB IT LU NL SE

W: AU DK JP NO

ZA 8507846 A 19860414 (198628)

AU 8548673 A 19860502 (198630)

EP 198893 A 19861029 (198644) EN

R: AT BE CH DE FR GB IT LI LU NL SE

NO 8602339 A 19860915 (198644)

CN 85108498 A 19860610 (198710)

JP 62500932 W 19870416 (198721)

DK 8602784 A 19860613 (198722)

US 4720489 A 19880119 (198805)

CA 1262335 A 19891017 (198947)

EP 198893 B 19920304 (199210)

R: AT BE CH DE FR GB IT LI LU NL SE

DE 3585526 G 19920409 (199216)

NZ 213805 A 19930428 (199320)

A61K007-06 <--

DK 166801 B 19930719 (199334)

A61K007-06 <--

NO 174832 B 19940411 (199418)

A61K031-56 <--

JP 06053680 B2 19940720 (199427)

5 A61K045-00

PH 26283 A 19920410 (199520) A61K031-165

ADT WO 8602269 A WO 1985-US2000 19851010; ZA 8507846 A ZA 1985-7846 19851011; EP 198893 A EP 1985-905536 19851010; JP 62500932 W JP 1985-504753 19851010; US 4720489 A US 1984-661019 19841015; NZ 213805 A NZ 1985-213805 19851014; DK 166801 B WO 1985-US2000 19851010, DK 1986-2784 19860613; NO 174832 B WO 1985-US2000 19851010, NO 1986-2339 19860611; JP 06053680 B2 JP 1985-504753 19851010, WO 1985-US2000 19851010; PH 26283 A PH 1985-32920 19851011

FDT DK 166801 B Previous Publ. DK 8602784; NO 174832 B Previous Publ. NO 8602339; JP 06053680 B2 Based on JP 62500932, Based on WO 8602269

PRAI US 1984-661019 19841015

REP DE 2840144; EP 16239; SSR880629; US 4201788; US 4390532; US 4439432; US 4457925; 3.Jnl.Ref; US 4456586

IC A61K007-06; A61K031-56; A61K045-00  
ICM A61K007-06; A61K031-165; A61K031-56; A61K045-00  
ICS A61K031-13; A61K031-195; A61K031-565; A61K031-57; A61K037-48

ICI A61K031-13, A61K031:

AB WO 8602269 A UPAB: 19930922  
A process of altering the rate and character of human hair growth comprises applying to the skin a compsn. containing a material capable of inhibiting the action of the enzyme ornithine decarboxylase (ODC). The compsn. may contain e.g. 2-(difluoromethyl)-2,5 -diaminopentanoic acid; alpha-ethynyl ornithine, 6-heptyne-2,5-diamine or 2-methyl-6-heptyne diamine. Prefd. application rate of the material is 50-500 microgram/sq.cm.  
The compsn. may also contain an anti-androgen material selected from 5-alpha-reductase inhibitors and cytoplasmic androgen receptor-binding agents.  
USE/ADVANTAGE - The rate and character of human hair growth, including male beard hair growth, can be altered. Unwanted interference with other bodily processes can be minimised or avoided.  
0/0

FS CPI

FA AB

MC CPI: B01-C04; B01-C05; B04-B04F; B04-C03D; B10-B01B; B10-B02J; B10-E04C; B12-G01A; D08-B

ABEQ DE 3585526 G UPAB: 19930922  
A process of altering the rate and character of human hair growth comprises applying to the skin a compsn. contg. a material capable of inhibiting the action of the enzyme ornithine decarboxylase (ODC). The compsn. may contain e.g. 2-(difluoromethyl)-2,5 -diaminopentanoic acid; alpha-ethynyl ornithine, 6-heptyne-2,5-diamine or 2-methyl-6-heptyne diamine. Prefd. application rate of the material is 50-500 microgram/sq.cm.  
The compsn. may also contain an anti-androgen material selected from 5-alpha-reductase inhibitors and cytoplasmic androgen receptor-binding agents.  
USE/ADVANTAGE - The rate and character of human hair growth, including male beard hair growth, can be altered. Unwanted interference with other bodily processes can be minimised or avoided. ()

ABEQ EP 198893 B UPAB: 19930922  
The cosmetic process of reducing the rate and altering the character of human hair growth which comprises the step of applying to the skin a composition containing a material capable of inhibiting the action of the enzyme ornithine decarboxylase.

ABEQ US 4720489 A UPAB: 19930922  
New process for redn. growth rate and altering character of human hair, esp. androgen stimulated male beard growth, comprises topical admin. of ornithine decarboxylase inhibitor, opt. with anti-androgen.  
Inhibitor may be 1-2000 (50-500)mcg/m2 2-(difluoromethyl)-2,5-

diaminopentanoic acid, alpha-ethynyl-ornithine, 6-heptyne-2,5-diamine or 2-methyl-6-heptyne diamine.

Antiandrogen may be 1-500 mcg/m2 (5 alpha,20-R)-4-diazo-21-hydroxy-20methyl-pregnan-3-one, (4R)-5-10-seco-19-nor-pregna-4,5-diene-3,10,20-trione, 4-androstene-3-one-17-carboxylic acid and its Me ester, 17-beta-N,N-diethylcarbamoyl-9-methyl-4-aza-5-alpha-androstane-3-one, 11-, 17- and 20-alpha-OH-progesterone, cyproterone acetate, chloromadinone acetate, 17-alpha-propyl (and allyl)testerosterone, alpha, alpha, alpha-trifluoro-2-methyl -4'-nitro-m-propionontoluidide, 6-alpha-bromo-17-beta-hydroxy -17-alpha-methyl-4-one-5-alpha-androstane-3-one, 17-beta-acetoxy-4-alpha-5-cyclo-A-homo-B-nor-4alpha--1-ene-3-one and spironolactone.

USE - Redn. of polyamine synthesis and cell growth and proliferation. Treatment of female hirsutism.

L25 ANSWER 15 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 1985-159178 [26] WPIX  
 CR 1990-044777 [06]  
 DNC C1985-069670  
 TI Topical compsn. containing anti-androgen(s) - for altering rate and character of androgen-stimulated hair growth.  
 DC B01 B05  
 IN BREUER, M M; SHANDER, D; USDIN, R V; VAN, DER LEE H; KASZYNSKI, E; USDIN, V R; KASZYNSKI, E G  
 PA (KASZ-I) KASZYNSKI E G; (HAND-I) HANDELMAN J H; (KASZ-I) KASZYNSKY E G; (KASZ-I) KASZUNSKI E G  
 CYC 16  
 PI WO 8502543 A 19850620 (198526)\* EN 15  
 RW: CH DE FR GB NL SE  
 W: AU DK JP NO  
 AU 8537458 A 19850626 (198536)  
 ZA 8409518 A 19850612 (198536)  
 NO 8503143 A 19851014 (198548)  
 EP 165970 A 19860102 (198602) EN  
 R: CH DE FR GB LI NL SE  
 JP 61500966 W 19860515 (198626)  
 DK 8503630 A 19850809 (198632)  
 CN 85101410 A 19870110 (198806)  
 CA 1251737 A 19890328 (198917)  
 CN 1047620 A 19901212 (199136)#  
 IT 1221006 B 19900621 (199216)  
 EP 165970 B1 19930303 (199309) EN 9 A61K031-56 <--  
 R: CH DE FR GB LI NL SE  
 DE 3486090 G 19930408 (199315) A61K031-56 <--  
 PH 26282 A 19920410 (199520) A61K031-56 <--  
 JP 07045382 B2 19950517 (199524) 6 A61K007-06 <--  
 DK 170726 B 19951227 (199606) A61K031-56 <--  
 ADT WO 8502543 A WO 1984-US1977 19841130; ZA 8409518 A ZA 1984-9518 19841206; EP 165970 A EP 1985-900364 19841130; JP 61500966 W JP 1985-500023 19841130; EP 165970 B1 WO 1984-US1977 19841130, EP 1985-900364 19841130; DE 3486090 G DE 1984-3486090 19841130, WO 1984-US1977 19841130, EP 1985-900364 19841130; PH 26282 A PH 1984-31556 19841210; JP 07045382 B2 WO 1984-US1977 19841130, JP 1985-500023 19841130; DK 170726 B WO 1984-US1977 19841130, DK 1985-3630 19850809  
 FDT EP 165970 B1 Based on WO 8502543; DE 3486090 G Based on EP 165970, Based on WO 8502543; JP 07045382 B2 Based on JP 61500966, Based on WO 8502543; DK 170726 B Previous Publ. DK 8503630  
 PRAI US 1983-560726 19831212; US 1985-807623 19851211  
 REP DE 2840144; SSR871104; US 4008802; US 4039669; US 4269831; US 4310523; US 4439432; US 4098802

IC ICM **A61K007-06; A61K031-56**  
 ICS A61K007-15; A61K031-555; A61K037-43  
 AB WO 8502543 A UPAB: 19950619  
 A topical compsn. for altering the rate and character of androgen-stimulated hair growth comprises at least one 5-alpha-reductase inhibitor (I) and/or cytoplasmic androgen receptor-binding agent (II), and a suitable carrier.  
 USE - The normal rate of mole beard hair growth is reduced and its character caused to revert toward the vellus state by the topical application of (I) and/or (II). By the proper selection of anti-androgen cpds. and their mode of use, unwanted interference with other androgen-mediated bodily processes can be minimised or avoided.  
 0  
 Dwg./0  
 FS CPI  
 FA AB  
 MC CPI: B01-C04; B01-C05; B01-C09; B01-D01; **B06-D18**; B10-F02; B12-A07; B12-G01; B12-L05  
 ABEQ EP 165970 B UPAB: 19930925  
 A cosmetic process for reducing the rate and altering the character of androgen-stimulated beard hair growth in intact, sexually mature males, which comprises applying to the skin a composition comprising at least one antiandrogen agent consisting of a 5-alpha-reductase inhibitor or a cytoplasmic androgen receptor-binding agent or a mixture thereof, and a dermatologically acceptable carrier.  
 0/0

L25 ANSWER 16 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN  
 AN 1984-277375 [45] WPIX  
 DNC C1984-117567  
 TI Agent for preventing white hair formation - containing oxidising agent and/or female hormone to activate melanin formation.  
 DC B05 D21  
 IN INABA, M  
 PA (MEDI-N) MED HAIR RES KK  
 CYC 9  
 PI EP 124077 A 19841107 (198445)\* EN 9  
 R: BE DE FR GB IT NL SE  
 AU 8427289 A 19841101 (198451)  
 JP 59204121 A 19841119 (198501)  
 EP 124077 B 19890927 (198939) EN  
 R: BE DE FR GB IT NL SE  
 DE 3479859 G 19891102 (198945)  
 ADT EP 124077 A EP 1984-104656 19840425; JP 59204121 A JP 1983-75976 19830428  
 PRAI JP 1983-75976 19830428  
 REP 2.Jnl.Ref; A3...8605; EP 76159; FR 2007366; No-SR.Pub; US 4021538; US 4390341

IC **A61K007-06; A61K031-56; A61K033-20**  
 AB EP 124077 A UPAB: 19930925  
 White hair-preventing agent contains at least 1 effective component from an oxidising agent and female hormone, in amount sufficient to activate tyrosinase or oxidising enzyme which serves to promote formation of melanin within follicle melanocytes. Pref. oxidising agents are stabilised ClO2, NaBrO3, sodium perborate and KBrO3. Pref. female hormone (oestradiol) is contained in a 60% alcohol solution at 5-10 mg/100 ml.. Pref. a solution of tyrosine or melanin intermediate is used before, after or together with the agent.  
 Concentration of stabilised ClO2 is pref. 100-500 ppm, that of NaBrO3 is 50,000-120,000 ppm, that of KBrO3 is 5-12% and that of sodium perborate is 5%. Malemin intermediates are e.g. dopa, dopa quinone and halladrome.

Synergism is observed if oxidising agent and female hormone are used together.

ADVANTAGE - Pigmented hair can be prevented from turning white and growth of pigmented hairs can be promoted.

0/0

FS CPI

FA AB

MC CPI: B01-A02; B05-A01A; B05-A01B; B05-C07; B10-A06; B10-B02E; B12-C09;  
B12-G04; B12-L05; D08-B03

L25 ANSWER 17 OF 17 WPIX COPYRIGHT 2004 THOMSON DERWENT on STN

AN 1983-45402K [19] WPIX

DNC C1983-044179

TI Depilation preventing hair tonic - obtd. by dissolving egg white in water, decomposing protein(s) by adding proteolytic enzyme trypsin, etc..

DC D21

PA (SHIO-I) SHIOZU S

CYC 1

PI JP 58055431 A 19830401 (198319)\* 2

PRAI JP 1981-152261 19810926

IC A61K007-06; A61K031-19; A61K037-18

AB JP 58055431 A UPAB: 19930925

Egg white is dissolved in pure water to convert it into amino acids and nearly all proteins are decomposed by the addition of a proteolytic enzyme trypsin. The aqueous solution is mixed with methionine as a source for SH and methyl gps. for enzymic actions, tocopherol hydrochloride, pyridoxine hydrochloride, salicylic acid, para-hydroxy benzoate, ethanol, and glycerine.

The hair tonic agent can effectively activate hair, fibril, and head skin when used by spreading or coating on the head portion of human body every day, greatly preventing the occurrence of the loss or depilation of hair and accelerating the growth and development of hair. The hair tonic agent can exhibit its excellent therapeutic effect on baldness.

FS CPI

FA AB

MC CPI: D05-A02; D08-B03

=> FIL STNGUIDE

=>